These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28649647)

  • 81. Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.
    Elwood PC; Morgan G; Pickering JE; Galante J; Weightman AL; Morris D; Kelson M; Dolwani S
    PLoS One; 2016; 11(4):e0152402. PubMed ID: 27096951
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative.
    Gong Z; Aragaki AK; Chlebowski RT; Manson JE; Rohan TE; Chen C; Vitolins MZ; Tinker LF; LeBlanc ES; Kuller LH; Hou L; LaMonte MJ; Luo J; Wactawski-Wende J
    Int J Cancer; 2016 Apr; 138(8):1915-27. PubMed ID: 26616262
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Characteristics of Exceptional or Super Responders to Cancer Drugs.
    Prasad V; Vandross A
    Mayo Clin Proc; 2015 Dec; 90(12):1639-49. PubMed ID: 26546106
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Hormonal impact on tumor growth and progression.
    Reznikov A
    Exp Oncol; 2015 Sep; 37(3):162-72. PubMed ID: 26422099
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Subverting Subversion: A Review on the Breast Cancer Microenvironment and Therapeutic Opportunities.
    Rothschild E; Banerjee D
    Breast Cancer (Auckl); 2015; 9(Suppl 2):7-15. PubMed ID: 26417204
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression.
    Giussani M; Merlino G; Cappelletti V; Tagliabue E; Daidone MG
    Semin Cancer Biol; 2015 Dec; 35():3-10. PubMed ID: 26416466
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
    J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Living outliers: experiences, insights and narratives of exceptional survivors of incurable cancer.
    Frenkel M; Gross S; Popper Giveon A; Sapire K; Hermoni D
    Future Oncol; 2015; 11(12):1741-9. PubMed ID: 26075442
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Presence of insulin-like growth factor binding proteins correlates with tumor-promoting effects of matrix metalloproteinase 9 in breast cancer.
    Park JH; Rasch MG; Qiu J; Lund IK; Egeblad M
    Neoplasia; 2015 May; 17(5):421-33. PubMed ID: 26025665
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.
    Levin MK; Wang K; Yelensky R; Cao Y; Ramos C; Hoke N; Pippen J; Blum JL; Brooks B; Palmer G; Palma N; Balasubramanian S; Ross JS; O'Shaughnessy J
    Cancer Med; 2015 Aug; 4(8):1289-93. PubMed ID: 25871911
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer.
    Greenlee H; Balneaves LG; Carlson LE; Cohen M; Deng G; Hershman D; Mumber M; Perlmutter J; Seely D; Sen A; Zick SM; Tripathy D;
    J Natl Cancer Inst Monogr; 2014 Nov; 2014(50):346-58. PubMed ID: 25749602
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial.
    Bower JE; Crosswell AD; Stanton AL; Crespi CM; Winston D; Arevalo J; Ma J; Cole SW; Ganz PA
    Cancer; 2015 Apr; 121(8):1231-40. PubMed ID: 25537522
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Response and acquired resistance to everolimus in anaplastic thyroid cancer.
    Wagle N; Grabiner BC; Van Allen EM; Amin-Mansour A; Taylor-Weiner A; Rosenberg M; Gray N; Barletta JA; Guo Y; Swanson SJ; Ruan DT; Hanna GJ; Haddad RI; Getz G; Kwiatkowski DJ; Carter SL; Sabatini DM; Jänne PA; Garraway LA; Lorch JH
    N Engl J Med; 2014 Oct; 371(15):1426-33. PubMed ID: 25295501
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The AURORA initiative for metastatic breast cancer.
    Zardavas D; Maetens M; Irrthum A; Goulioti T; Engelen K; Fumagalli D; Salgado R; Aftimos P; Saini KS; Sotiriou C; Campbell P; Dinh P; von Minckwitz G; Gelber RD; Dowsett M; Di Leo A; Cameron D; Baselga J; Gnant M; Goldhirsch A; Norton L; Piccart M
    Br J Cancer; 2014 Nov; 111(10):1881-7. PubMed ID: 25225904
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.
    Al-Ahmadie H; Iyer G; Hohl M; Asthana S; Inagaki A; Schultz N; Hanrahan AJ; Scott SN; Brannon AR; McDermott GC; Pirun M; Ostrovnaya I; Kim P; Socci ND; Viale A; Schwartz GK; Reuter V; Bochner BH; Rosenberg JE; Bajorin DF; Berger MF; Petrini JH; Solit DB; Taylor BS
    Cancer Discov; 2014 Sep; 4(9):1014-21. PubMed ID: 24934408
    [TBL] [Abstract][Full Text] [Related]  

  • 97. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
    Mokrim M; Aftimos PG; Errihani H; Piccart-Gebhart M
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24748142
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
    Wagle N; Grabiner BC; Van Allen EM; Hodis E; Jacobus S; Supko JG; Stewart M; Choueiri TK; Gandhi L; Cleary JM; Elfiky AA; Taplin ME; Stack EC; Signoretti S; Loda M; Shapiro GI; Sabatini DM; Lander ES; Gabriel SB; Kantoff PW; Garraway LA; Rosenberg JE
    Cancer Discov; 2014 May; 4(5):546-53. PubMed ID: 24625776
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer.
    Mohr SB; Gorham ED; Kim J; Hofflich H; Garland CF
    Anticancer Res; 2014 Mar; 34(3):1163-6. PubMed ID: 24596354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.